Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.65 |
| ▸ | TK1 | P04183 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TYMS | P04818 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6842685 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL2623807 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL13273272 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL7653783 | 1.00 | RNASE1 (0.65) | RNASE1TK1BCHEPOLBTYMS | |
| SCHEMBL30698170 | 0.91 | RNASE1 (0.61) | RNASE1TK1BCHETYMSUPP1 | |
| SCHEMBL6542150 | 0.91 | RNASE1 (0.61) | RNASE1TK1BCHETYMSUPP1 | |
| SCHEMBL22992340 | 0.89 | RNASE1 (0.82) | RNASE1TK1 | |
| SCHEMBL9326675 | 0.89 | RNASE1 (0.82) | RNASE1TK1 | |
| SCHEMBL13273344 | 0.89 | RNASE1 (0.68) | RNASE1POLBTYMS | |
| SCHEMBL21886791 | 0.89 | RNASE1 (0.82) | RNASE1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| EP-2607370-A2 | Amorphous form of beta- L-2'-deoxythymidine | Novartis AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| EP-2415776-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20100048504-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF BETA-L-DEOXYTHYMIDINE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-7589079-B2 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine | NOVARTIS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | IDENIX PHARMACEUTICALS INC. | 2008-07-31 | — | — | US | disclosed |
| US-7323451-B2 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine | IDENIX PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323451-B2 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine | IDENIX PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20080015350-A1 | Crystalline and amorphous forms of beta-L-2'-deoxythymidine | NOVARTIS AG (CH) | 2008-01-17 | — | — | US | disclosed |
| US-7304043-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087995-A1 | beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | RNASE1 473/4885TK1 34/4885BCHE 1464/4885 |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | RNASE1 473/4885TK1 34/4885BCHE 1464/4885 |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | RNASE1 1059/4885TK1 147/4885BCHE 477/4885 |
| US-20080015350-A1 | Crystalline and amorphous forms of beta-L-2'-deoxythymidine | TYMP, PYGL, TTR | RNASE1 41/4885TK1 93/4885BCHE 637/4885 |
| US-20080182814-A1 | Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | SLC28A2, SLC28A1, SLC29A2 | RNASE1 927/4885TK1 161/4885BCHE 482/4885 |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | RNASE1 473/4885TK1 34/4885BCHE 1464/4885 |
| US-20100048504-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF BETA-L-DEOXYTHYMIDINE | TYMP, PYGL, TTR | RNASE1 50/4885TK1 91/4885BCHE 642/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | RNASE1 473/4885TK1 34/4885BCHE 1464/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | RNASE1 473/4885TK1 34/4885BCHE 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.